Home > Healthcare > Biotechnology > Bioservices > Upstream Bioprocessing Market

Upstream Bioprocessing Market Trends

  • Report ID: GMI8437
  • Published Date: Mar 2024
  • Report Format: PDF

Upstream Bioprocessing Market Trends

  • Single-use bioprocessing systems offer numerous advantages over traditional stainless-steel systems. It offers several advantages including flexibility, reduced risk of cross-contamination, and faster turnaround time. Therefore, the growing acceptance of single-use bioreactors has resulted in development and technological advancement in bioreactors. For instance, in March 2021, Thermo Fisher Scientific launched large-scale single-use bioreactor systems with capacities beyond the standard limits. Thus, availability of such products/systems in the market is expected to spur the market growth.
     
  • Further, the rising implementation of Process Analytical Technology (PAT) revolutionizes upstream bioprocessing by enabling real-time monitoring, analysis, and control of critical process parameters (CPPs) and quality attributes. PAT provides insights into bioprocesses, facilitating process optimization and improving product quality.
     

Therefore, the adoption of single-use bioprocessing systems and the implementation of PAT drive the growth in the market by enhancing efficiency, flexibility, and product quality.
 

Authors: Mariam Faizullabhoy, Gauri Wani

Frequently Asked Questions (FAQ) :

The upstream bioprocessing market was valued at USD 9.5 billion in 2023 and is anticipated to record 9.7% CAGR over 2024-2032, owing to the increasing demand for biopharmaceuticals caused by high prevalence of chronic diseases.

The bioreactors/fermenters segment accounted for a share of 48.6% in market in 2023 and will grow significantly through 2032 as these vessels provide a controlled environment for the proliferation of cells or microorganisms, essential to produce biopharmaceuticals, enzymes, vaccines, and other bioproducts.

North America upstream bioprocessing industry is estimated to reach over USD 9.5 billion by 2032 attributed to the increasing collaboration & partnerships with an aim of improving awareness and education related to bioprocessing.

Applikon Biotechnology, Boehringer Ingelheim GmbH, CellGenix GmbH, Corning, Inc., Danaher Corporation (Cytvia), Eppendorf AG, Merck KGaA, PBS Biotech, Inc., Sartorius AG, and Thermo Fisher Scientific Inc.

Upstream Bioprocessing Market Scope

Buy Now


Premium Report Details

  • Base Year: 2023
  • Companies covered: 10
  • Tables & Figures: 301
  • Countries covered: 19
  • Pages: 171
 Download Free Sample